Anticoagulants - Dabigatran (Pradaxa)
Customize your policy alerts
Sign up for Cigna Policy IP0033 alerts
Get alerted when Policy IP0033 changes without checking for updates manually.
Monitor payer policy activity
Coverage, prior authorization, and preferred product criteria for dabigatran (Pradaxa) formulations including capsules and oral pellets for prevention and treatment of thromboembolic conditions for Cigna plans.
An age restriction was added to multiple indications including atrial fibrillation, DVT/PE treatment and prophylaxis, and other thromboembolic-related conditions.
Removed the requirement for 5 days of parenteral anticoagulant therapy for Pradaxa oral pellets used for treatment of venous thromboembolic events.
Preferred product criteria were updated to extend preferred-product approaches across Pradaxa capsule strengths and to clarify criteria when a brand is required due to inactive ingredient differences.
Prior authorization requirements for generic dabigatran capsules were removed for Employer and Individual and Family plans.
Documentation requirements were removed from coverage language for certain Pradaxa oral pellet indications.
Coverage Criteria Summary
Revised coverage highlights
Policy updates and criteria highlights from the revision history
Added across multiple indications
Facilitates direct oral initiation
Applies to Employer and Individual/Family Plans; approach extended across capsule strengths
See full policy for exact age/weight thresholds
Not covered: The policy identifies thromboembolism in individuals with Factor V Leiden thrombophilia and antiphospholipid syndrome as non‑covered indications for dabigatran (Pradaxa). This listing appears in the Conditions Not Covered / exclusion notes and should be applied when assessing medical necessity for these specific thromboembolic contexts.
Revision history clarifies that the earlier listing of Prophylaxis of Venous Thromboembolism in Individuals with Factor V Leiden was removed from the Conditions Not Covered section. However, the revision also documents that thromboembolism in individuals with Factor V Leiden thrombophilia and antiphospholipid syndrome are noted as non‑covered indications elsewhere in the revision notes. Apply the current exclusion language in the policy when determining coverage for patients with these conditions.
Provider Actions, Prior Authorization & Documentation
Prior authorization removed for generic dabigatran capsules
Prior authorization (PA) is no longer required for generic dabigatran capsules for Employer and Individual/Family plans; brand Pradaxa capsules and oral pellets remain subject to the policy's preferred-product criteria and any applicable prior authorization rules.
- Removed prior authorization requirements for generic dabigatran capsules on all Employer plans and Individual and Family plans.
Step/try requirement updated to 'has tried' listed anticoagulants
Step/try language was revised: providers must document that the patient has tried warfarin, fondaparinux, or a low‑molecular‑weight heparin (e.g., enoxaparin, dalteparin) or that the patient has been started on dabigatran/Pradaxa (language changed from requiring ‘failure, contraindication or intolerance’ to 'has tried').
- Applies to Pradaxa capsules and oral pellets for treatment or prevention of other thromboembolic‑related conditions.
- Also applies when determining need for brand Pradaxa versus generic capsule trial.
Documentation requirements removed for some Pradaxa oral pellet indications; prescriber attestation still needed for brand exceptions
Documentation requirements were removed from the coverage language for certain Pradaxa oral pellet indications; however prescriber attestation remains necessary when justifying brand use due to inactive ingredient differences.
- Removed documentation requirements for Pradaxa oral pellets (continuation/on‑treatment language changed to 'Patient is currently').
- Prescriber statement is required to attest that inactive ingredient differences would result in a significant allergy or serious adverse reaction when requesting brand due to formulation differences.
Denial risk if preferred‑product criteria or prescriber attestation not provided
Failure to meet the updated preferred‑product criteria or to provide prescriber attestation that the patient tried the bioequivalent generic capsule and cannot take it due to inactive ingredient differences may result in coverage denial or refusal to approve brand Pradaxa.
- Preferred‑product table requires trial of the bioequivalent generic capsule and a prescriber statement that inactive ingredient differences (e.g., dyes, fillers, preservatives) would cause a significant allergy or serious adverse reaction for brand to be allowed.
- Generic dabigatran capsules no longer require PA on Employer and Individual/Family plans; requests for brand without meeting criteria risk denial.
Initial Therapy Requirements
Initial therapy requirement
Initial therapy and prior treatment expectations updated
Wording changed from 'failure/contraindication/intolerance' to 'has tried'; applies to treatment or prevention of other thromboembolic-related conditions
Continuation and Ongoing Use
Continuation therapy notes
Continuation and ongoing use notes reflected in preferred product language updates.
See full policy for specific continuation conditions; prescriber documentation may still be required to justify brand use for inactive ingredient differences
Applies to Employer and Individual/Family Plans
Step Therapy Table
| Step | Requirement | Brand exception |
|---|---|---|
| 1 | Patient has tried warfarin, fondaparinux, or a low molecular weight heparin product (e.g., enoxaparin, dalteparin) OR patient has been started on dabigatran/Pradaxa. | If brand Pradaxa (75 mg, 110 mg, 150 mg) is requested, patient must have tried the bioequivalent dabigatran capsule AND, per the prescriber, cannot take the generic capsule due to a formulation difference in inactive ingredient(s) (e.g., dyes, fillers, preservatives) that would result in a significant allergy or serious adverse reaction. |
Definitions & Preferred Product Criteria
Background
Background: Dabigatran (Pradaxa) is an oral direct thrombin inhibitor used for prevention and treatment of venous thromboembolism and for stroke prevention in atrial fibrillation. The policy updates reflect formulation‑specific rules for capsules and oral pellets, age restrictions added to multiple indications, and changes to prior authorization and preferred‑product requirements for Cigna Employer and Individual/Family plans.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.